表紙
市場調査レポート

未分化大細胞リンパ腫(ALCL):パイプライン分析

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 257813
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
未分化大細胞リンパ腫(ALCL):パイプライン分析 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 112 Pages
概要

未分化大細胞リンパ腫(ALCL)は、まれなタイプの非ホジキンリンパ腫です。これらの細胞は、リンパ節に蓄積されます。また、皮膚や肺など、体の他の部位でも生じます。頸部・腋窩・鼠径部の無痛性の腫脹、咳や息切れ、寝汗、高温や体重減少、食欲不振、疲労などの症状が見られます。治療には、化学療法、放射線療法などが含まれます。

当レポートでは、未分化大細胞リンパ腫(ALCL)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

未分化大細胞リンパ腫(ALCL)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • Seattle Genetics, Inc.
  • Teva Pharmaceutical Industries Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AdIL-24
  • AKR-302
  • AKR-303
  • AZD-3463
  • brentuximab vedotin
  • CEP-28122
  • CEP-37440
  • copanlisib hydrochloride
  • crizotinib
  • Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma
  • KRA-0008
  • SH-7129
  • Small Molecules to Inhibit Aurora and ALK Kinase for Oncology
  • Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7664IDB

Summary

Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
  • The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects
  • The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaplastic Large Cell Lymphoma (ALCL) Overview
  • Therapeutics Development
    • Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview
    • Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis
  • Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies
  • Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies
  • Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development
    • Ariad Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Celon Pharma Sp. z o.o.
    • Pfizer Inc.
    • Sareum Holdings Plc
    • Seattle Genetics, Inc.
    • Teva Pharmaceutical Industries Limited
  • Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AdIL-24 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-3463 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brigatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEP-28122 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEP-37440 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KRA-0008 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates
  • Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects
  • Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products
  • Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma
      • Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
      • Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
      • Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
      • Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
      • Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting
      • Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
      • Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan
      • Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
      • Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2016
  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H1 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2016
  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top